4732 Results for "

Antitumor Activity

" in MedChemExpress (MCE) Product Catalog:
Products (4732)

4732 Results for "Antitumor Activity" in MCE Product Catalog:

878
878 Publications Verification
Cat. No.: HY-15763
CAS No.: 571203-78-6
Purity:  99.62%
Research Areas:  

Cancer

Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
loading...
    loading...
193
193 Cited Publications
Cat. No.: HY-50846
CAS No.: 942183-80-4
Target:  

ERK

Research Areas:  

Neurological Disease Cancer

SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-naive and MAPK inhibitor-resistant cells containing BRAF or RAS mutations .
loading...
    loading...
179
179 Cited Publications
Cat. No.: HY-10181A
CAS No.: 854001-07-3
Purity:  98.86%
Synonyms: BMS-354825 hydrochloride
Research Areas:  

Cancer

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib hydrochloride also induces apoptosis and autophagy.
loading...
    loading...
179
179 Cited Publications
Cat. No.: HY-10181B
CAS No.: 863127-77-9
Purity:  99.58%
Synonyms: BMS-354825 monohydrate
Research Areas:  

Cancer

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
loading...
    loading...
179
179 Cited Publications
Cat. No.: HY-10181
CAS No.: 302962-49-8
Purity:  99.83%
Synonyms: BMS-354825
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy, and can cross the blood-brain barrier .
loading...
    loading...
161
161 Cited Publications
Cat. No.: HY-16749
CAS No.: 1029044-16-3
Synonyms: PLX-3397
Target:  

c-Fms c-Kit Apoptosis

Research Areas:  

Cancer

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity. Pexidartinib has limited permeability to the blood-brain barrier, primarily through ABCB1 .
loading...
    loading...
110
110 Cited Publications
Cat. No.: HY-12248
CAS No.: 1439399-58-2
Purity:  99.82%
Synonyms: CB-839
Target:  

Glutaminase Autophagy

Research Areas:  

Cancer

Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .
loading...
    loading...
110
110 Cited Publications
Cat. No.: HY-12248A
CAS No.: 1874231-60-3
Synonyms: CB-839 hydrochloride
Target:  

Glutaminase Autophagy

Research Areas:  

Cancer

Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity .
loading...
    loading...
106
106 Cited Publications
Cat. No.: HY-16106
CAS No.: 1207456-01-6
Synonyms: BMN-673; LT-673
Target:  

PARP

Research Areas:  

Cancer

Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .
loading...
    loading...
101
101 Cited Publications
Cat. No.: HY-10981
CAS No.: 417716-92-8
Purity:  99.75%
Synonyms: E7080
Target:  

VEGFR FGFR PDGFR c-Kit RET

Research Areas:  

Cancer

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
101
101 Cited Publications
Cat. No.: HY-10981A
CAS No.: 857890-39-2
Purity:  99.86%
Synonyms: E7080 mesylate
Target:  

VEGFR FGFR PDGFR RET c-Kit

Research Areas:  

Cancer

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
97
97 Cited Publications
Cat. No.: HY-15575
CAS No.: 646502-53-6
Purity:  99.94%
Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
loading...
    loading...
96
96 Cited Publications
Cat. No.: HY-10331
CAS No.: 755037-03-7
Purity:  99.93%
Synonyms: BAY 73-4506
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
96
96 Cited Publications
Cat. No.: HY-10331A
CAS No.: 1019206-88-2
Purity:  99.96%
Synonyms: BAY 73-4506 monohydrate
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-10619B
CAS No.: 1038915-73-9
Purity:  99.99%
Synonyms: MK-4827 tosylate
Target:  

PARP Apoptosis

Research Areas:  

Cancer

Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-10619
CAS No.: 1038915-60-4
Purity:  99.96%
Synonyms: MK-4827
Target:  

PARP Apoptosis

Research Areas:  

Cancer

Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-10619A
CAS No.: 1038915-64-8
Purity:  99.41%
Synonyms: MK-4827 hydrochloride
Target:  

PARP Apoptosis

Research Areas:  

Cancer

Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
86
86 Cited Publications
Cat. No.: HY-10619E
CAS No.: 1613220-15-7
Purity:  99.97%
Synonyms: MK-4827 tosylate hydrate
Target:  

PARP Apoptosis

Research Areas:  

Cancer

Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
81
81 Cited Publications
Cat. No.: HY-16568
CAS No.: 136572-09-3
Synonyms: (+)-Irinotecan hydrochloride trihydrate; CPT-11 hydrochloride trihydrate
Target:  

Topoisomerase Autophagy

Research Areas:  

Cancer

Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
loading...
    loading...
75
75 Cited Publications
Cat. No.: HY-10971
CAS No.: 1028486-01-2
Purity:  99.36%
Synonyms: MLN 8237
Research Areas:  

Cancer

Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
loading...
    loading...